The relationship between age and the effect of adjuvant therapies in women with primary breast cancer.
| dc.contributor.author | Howell, Anthony | |
| dc.date.accessioned | 2010-09-10T16:01:13Z | |
| dc.date.available | 2010-09-10T16:01:13Z | |
| dc.date.issued | 1989 | |
| dc.identifier.citation | The relationship between age and the effect of adjuvant therapies in women with primary breast cancer. 1989, 32 Suppl 1:231-7 Horm Res | en |
| dc.identifier.issn | 0301-0163 | |
| dc.identifier.pmid | 2613208 | |
| dc.identifier.doi | 10.1159/000181354 | |
| dc.identifier.uri | http://hdl.handle.net/10541/111035 | |
| dc.description.abstract | Apparent differences in the effectiveness of adjuvant therapies according to age, has led to controversy concerning the optimum treatment for women with breast cancer above and below 50 years of age. The data upon which this controversy is based and the possible reasons why chemotherapy appears more active in young women, whilst endocrine therapy appears more active in older women, is examined. | |
| dc.language.iso | en | en |
| dc.subject | Anticancerous Agents | en |
| dc.subject | Breast Cancer | en |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Age Factors | |
| dc.subject.mesh | Antineoplastic Agents | |
| dc.subject.mesh | Breast Neoplasms | |
| dc.subject.mesh | Drug Evaluation | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Tamoxifen | |
| dc.title | The relationship between age and the effect of adjuvant therapies in women with primary breast cancer. | en |
| dc.type | Article | en |
| dc.identifier.eissn | 1423-0046 | |
| dc.contributor.department | Department of Medical Oncology, Christie Hospital, Manchester, UK. | en |
| dc.identifier.journal | Hormone Research | en |
| html.description.abstract | Apparent differences in the effectiveness of adjuvant therapies according to age, has led to controversy concerning the optimum treatment for women with breast cancer above and below 50 years of age. The data upon which this controversy is based and the possible reasons why chemotherapy appears more active in young women, whilst endocrine therapy appears more active in older women, is examined. |